Lutetium Lu 177 dotatate

Lutetium Lu 177 dotatate Brand Name– Lutathera

What is Lutetium Lu 177 dotatate

Lutetium Lu 177 dotatate is a radiolabeled somatostatin analog indicated for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in adults.

Premedicate with antiemetics as well as an amino acid solution.

Because lutetium Lu 177 dotatate is a radiopharmaceutical, appropriate safety measures should be undertaken to minimize radiation exposure

Indications

  • malignant neuroendocrine tumor (NET)

For the treatment of somatostatin receptor-positive gastroenteropancreatic malignant neuroendocrine tumor (NET), including foregut, midgut, and hindgut neuroendocrine tumors

Side Effects

  1. abdominal pain
  2. abdominal pain
  3. alopecia
  4. anemia
  5. anorexia
  6. anxiety
  7. anxiety
  8. atrial fibrillation
  9. atrial fibrillation
  10. azotemia
  11. back pain
  12. back pain
  13. bronchospasm
  14. cholestasis
  15. colic
  16. constipation
  17. cough
  18. cough
  19. diarrhea
  20. diarrhea
  21. dizziness
  22. dysgeusia
  23. dysuria
  24. elevated hepatic enzymes
  25. elevated hepatic enzymes
  26. fatigue
  27. fatigue
  28. fever
  29. flushing
  30. flushing
  31. headache
  32. heart failure
  33. hyperbilirubinemia
  34. hyperbilirubinemia
  35. hyperglycemia
  36. hyperglycemia
  37. hyperkalemia
  38. hypernatremia
  39. hypertension
  40. hypertension
  41. hyperuricemia
  42. hyperuricemia
  43. hypocalcemia
  44. hypoglycemia
  45. hypokalemia
  46. hypokalemia
  47. hypotension
  48. leukopenia
  49. leukopenia
  50. lymphopenia
  51. lymphopenia
  52. myalgia
  53. myocardial infarction
  54. nausea
  55. nausea
  56. neuroendocrine hormonal crisis
  57. neutropenia
  58. neutropenia
  59. new primary malignancy
  60. nocturia
  61. pelvic pain
  62. peripheral edema
  63. renal failure (unspecified)
  64. renal failure (unspecified)
  65. thrombocytopenia
  66. thrombocytopenia
  67. urethral pain
  68. urinary incontinence
  69. vomiting
  70. vomiting

Monitoring Parameters

  • CBC with differential
  • LFTs
  • pregnancy testing
  • serum albumin
  • serum creatinine

Contraindications

  • anemia
  • bone marrow suppression
  • breast-feeding
  • contraception requirements
  • hepatic disease
  • infertility
  • neuroendocrine hormonal crisis
  • neutropenia
  • new primary malignancy
  • pregnancy
  • pregnancy testing
  • radiation exposure
  • renal disease
  • renal impairment
  • reproductive risk
  • thrombocytopenia

Interactions

  • Lanreotide
  • Octreotide
  • Palifermin
  • Penicillamine
  • Tuberculin Purified Protein Derivative, PPD